Global Lupus Nephritis Treatment Market Set to Surpass USD 5.67 Billion by 2033 at a 11% CAGR, Driven by Innovative Therapies and Increased Disease Awareness

Lupus Nephritis Treatment Market

The global lupus nephritis treatment market, which reached a valuation of US$ 1.8 billion in 2022, is anticipated to expand at a robust CAGR of 11% over the forecast period from 2023 to 2033, ultimately accumulating a projected market value of US$ 5.67 billion. The steady growth trajectory of the market is underpinned by a notable increase in the prevalence of lupus nephritis, heightened awareness of the condition, and a wave of novel treatments and therapeutic innovations entering the market. During the historical period from 2018 to 2022, the market registered a CAGR of 6.5%, reflecting a consistent rise in demand for effective and advanced treatments.

Lupus nephritis, a severe complication of systemic lupus erythematosus (SLE), has prompted a pressing need for targeted treatment solutions as cases continue to rise worldwide. Governments, healthcare providers, and pharmaceutical companies are increasingly prioritizing lupus nephritis in their efforts, contributing to market growth. Additionally, the development of biologics and immunosuppressants tailored for lupus nephritis is enabling patients to better manage the disease, thus driving demand.

Which are Some Prominent Drivers of Lupus Nephritis Treatment Market?

Increasing prevalence of lupus nephritis and advancements in drug development driving market growth for market

The prevalence of lupus nephritis has been on the rise in recent years, which has led to an increase in the demand for its treatment. There has been significant progress in the development of drugs that target lupus nephritis, which has led to the availability of new treatment options. These new drugs are more effective than previous treatments, which has contributed to market growth.

As more people become aware of lupus nephritis and its symptoms, the demand for treatment is likely to increase. As healthcare expenditure continues to rise globally, patients with lupus nephritis are more likely to seek treatment, which is driving market growth.

Governments in several countries are taking initiatives to increase awareness about lupus nephritis and provide access to affordable treatment, which is also contributing to market growth.

Availability of medications boosting market growth for lupus nephritis treatment market

Immunosuppressants: These drugs work by suppressing the immune system, which can help reduce inflammation in the kidneys. Examples include cyclophosphamide, mycophenolate mofetil, and azathioprine.

Corticosteroids: These drugs are anti-inflammatory and can help reduce inflammation in the kidneys. Examples include prednisone and methylprednisolone.

Biologic drugs: These drugs target specific molecules in the immune system that are involved in the development of lupus nephritis. Examples include belimumab and rituximab.

ACE inhibitors and angiotensin receptor blockers (ARBs): These drugs are used to lower blood pressure and reduce proteinuria (protein in the urine), which can help protect the kidneys.

Plasma exchange: This treatment involves removing the plasma (the liquid part of the blood) and replacing it with donor plasma. It can help remove harmful antibodies from the bloodstream and reduce inflammation in the kidneys.

Kidney transplant: In severe cases of lupus nephritis, a kidney transplant may be necessary if the kidneys are no longer functioning properly.

Market Competition

Key players in the lupus nephritis treatment are Roche, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, AstraZeneca, Aurinia Pharmaceuticals Inc., Johnson & Johnson Private Limited, Bayer AG, Sanofi, Sun Pharmaceutical Industries Ltd and Abbott

• Roche has developed Belimumab, a monoclonal antibody that targets B-lymphocyte stimulator (BLyS), a protein involved in the activation of B-cells that contribute to the immune response in lupus. Belimumab was the first FDA-approved drug specifically for the treatment of lupus in over 50 years. It is used to treat systemic lupus erythematosus (SLE) and has shown efficacy in reducing disease activity and flares in patients with lupus nephritis.
• BMS developed Orencia, a selective T-cell costimulation modulator, which is used to treat rheumatoid arthritis and juvenile idiopathic arthritis. In a Phase II clinical trial, abatacept was found to reduce proteinuria and improve renal function in patients with lupus nephritis.

Key Companies Profiled

• Roche
• Bristol-Myers Squibb
• Eli Lilly and Company
• GlaxoSmithKline
• AstraZeneca
• Aurinia Pharmaceuticals Inc.
• Johnson & Johnson Private Limited
• Bayer AG
• Sanofi
• Sun Pharmaceutical Industries Ltd
• Abbott

A Full Report Overview

Key Segments Profiled in the Lupus Nephritis Treatment Market Survey

Drug Class:

• Corticosteroids
• Immunosuppressive
  • Azathioprine
  • Cyclophosphamide
  • Mycophenolate
• Belimumab

Route of Administration:

• Oral
• Parenteral

Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube